Testing empagliflozin for heart and kidney health
Treatments studied
Part of Heart & circulation, Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial tests if the drug empagliflozin can improve kidney function in people hospitalized with heart failure who also develop acute kidney injury. It may help protect the kidneys while treating the heart condition.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You are in the hospital for heart failure (new or worsening).
- You have signs of acute kidney injury or a high level of a kidney protein called NGAL in your urine.
- You can start the study drug within 12 hours of the kidney injury diagnosis.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether empagliflozin, a medication for heart failure, can help people who also have end-stage kidney disease and are on dialysis. It aims to see if the drug improves heart function in this group.
This trial tests a medicine called empagliflozin (usually used for diabetes) to see if it can help people with very advanced kidney disease and diabetes. The study will check if this drug can slow down further kidney damage and improve overall kidney health.
This study tests whether a medication called empagliflozin (a type of drug that helps protect the kidneys) can improve blood vessel health in people with chronic kidney disease who do not have diabetes. It may help slow kidney decline and reduce heart risks.
This trial tests whether a medicine called empagliflozin (used for diabetes and heart failure) can help people with both heart failure (with preserved pumping ability) and end-stage kidney disease who are on dialysis. The study looks at how the drug affects heart function and overall well-being.
This trial tests whether empagliflozin, a medication originally for diabetes, can help protect the remaining kidney function in people who have just started peritoneal dialysis. If you started dialysis within the last 3 months and still make some urine, this study may be a good fit.
This study tests whether the medicine empagliflozin is safe and helpful for adults who are on regular hemodialysis and still make a small amount of urine. The goal is to see if it can improve health outcomes while tracking side effects closely.
Hear when a new Empagliflozin in Cardiorenal Syndrome Type 1 trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.